CAR T- Cell therapy in Israel is growing at a very rapid pace. Sheba and Ichilov hospitals in Tel Aviv, Israel have already started CAR T-cell therapy. Sheba hospital is making their own CAR T-cells and thus restricts themselves to treatment of some type of leukemia, lymphoma and myeloma. On the other hand Ichilov hospital is using CAR T-cells of Novrtis and thus has more types of cancer to treat.
Israel’s extensive explorations and breakthroughs in the search of novel target antigens, optimization of CAR structure, cocktail CAR-T therapy, combination therapy, and extension of CAR-T cell applications, imply that we are currently on the verge of a revolution in CAR-T therapy. US FDA has approved CAR T Cell therapy for relapsed B Acute lymphoblastic leukemia, lymphoma & multiple myeloma.
CAR T-Cell therapy is a form of immunotherapy that uses specially modified T-cells which are part of our immune system to fight cancer. A sample of patients T cells are collected from the blood, then it is modified to produce special structures called chimeric antigen receptors (CAR) on their surface. When these modified CAR cells are re infused in the patient, these new cells attack the specific antigen and kills the tumor cells.
CAR T-cell therapy takes help from body’s own immune system to attack and kill cancer cells. This is done by removing some specified cells from the blood of the patient, modifying them in the lab and re-injecting them into the patient. CAR T-cell therapy has produced very encouraging results in Non-Hodgkin lymphoma and thus approved by FDA.
At present FDA has approved CAR T-Cell therapy for some forms of aggressive and refractory Non-Hodgkin lymphoma and relapsed and refractory acute lymphoblastic leukemia. Patient need to send full medical reports to ascertain the use of CAR T-Cell therapy for his treatment.
1. Patients with CD19+ B-cell Lymphoma(At least 2 prior combination chemotherapy regimens)
2. To be aged 3 to 75 years
3. ECOG score ≤2
4. Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time.
1. Intracranial hypertension or unconsciousness
2. Respiratory failure
3. Disseminated intravascular coagulation
4. Hematosepsis or Uncontrolled active infection
5. Uncontrolled diabetes
1. Examination & test: one week
2. Pre-treatment & T-Cell Collection: one week
3. T-Cell preparation & return: two-three weeks
4. 1st Effectiveness analysis: three weeks
5. 2nd Effectiveness analysis: three weeks
The common side effects of CAR T-cell therapy include:
CAR T-cell therapy for the treatment of lymphoma and other blood cancers has shown promising outcomes. Since CAR T-cell treatment, many patients who had previously relapsed blood tumours had promising results and no evidence of cancer. It has also aided in the rehabilitation of patients who have previously failed to respond to most traditional cancer therapies.
However, longer-term studies for a larger patient population are needed to validate the efficacy of this treatment. Large-scale experiments would also aid in determining the likelihood of side effects and the right ways to deal with them.
Israel is among the world leader in CAR-T cell therapy & BMT. Cost of CAR T-cell therapy in Sheba hospital, Israel comes out to be around $150,000 USD and in Ichilov hospital is around $ 510,000 USD.
Also read this : CAR T Cell therapy in India
Patient can call +91 96 1588 1588 or email to cancerfax@gmail.com with patient details and medical reports and we shall arrange for second opinion, treatment plan, estimate of expenses, medical visa, local guest house and all kind of local help.